Diabetes has been reported to be a significant risk factor for the severity of the disease in Covid-19 cases. Now more than ever, the management and control of blood sugar levels, also in Type 2 Diabetes and pre-diabetes, is vital.
There is real evidence that people with diabetes and pre-diabetes are very susceptible to the corona virus.
It is a fact that people with diabetes are at increased risk of infections including influenza and for related complications such as secondary bacterial pneumonia. This is now even more true with the COVID-19 virus.
Many patients with type 2 diabetes are also obese and obesity is also a risk factor for more severe infection and a poor outcome.
Recent case studies reveal that Diabetes may be an independent risk factor for rapid progression and poor prognosis of COVID-19 through several known pathways and a possible new one: direct damage to pancreatic islets.
Taken all together, patients with diabetes are a high-risk and complicated group of patients to treat for COVID-19, with an increased requirement of hospitalisation. Patients with diabetes need intensive attention to reduce the risk of fatalities.
As a first line of defense, patients with diabetes and pre-diabetes should follow the general prevention advice given by the authorities thoroughly to avoid infection with COVID-19.
Secondly, managing and controlling blood sugar levels through the correct diet (TLC-Program) and lifestyle is especially important now. Improving blood sugar levels through diet will reduce risk factors associated with the disease.
More than ever before, it is vital to start following your TLC-Program 100%. If you do not have a Program yet, buy here: https://tlcforwellbeing.com/product-category/tlc-online-programs/
(Some extracts from published research:
Diabetes is a risk factor for hospitalisation and mortality of the COVID-19 infection. Diabetes was a comorbidity in 22% of 32 non-survivors in a study of 52 intensive care patients. In another study of 173 patients with severe disease, 16.2% had diabetes, and in further study of 140 hospitalised patients, 12% had diabetes. When comparing intensive care and non-intensive care patients with COVID-19, there appears to be a twofold increase in the incidence of patients in intensive care having diabetes. Mortality seems to be about threefold higher in people with diabetes compared with the general mortality of COVID-19 in China. The number of comorbidities is a predictor of mortality in COVID-19. In addition to diabetes, the other common comorbidities were hypertension, in about 20% of cases, cardiovascular disease (16%), and lung disease (6%).
Diabetes patients have impaired immune-response to infection both in relation to cytokine profile and to changes in immune-responses including T-cell and macrophage activation. Poor glycaemic control impairs several aspects of the immune response to viral infection and also to the potential bacterial secondary infection in the lungs.)